0000000000918299

AUTHOR

L. Rubio

showing 7 related works from this author

PCA3 como biomarcador de segunda línea en un programa de screening oportunista prospectivo, aleatorizado y controlado

2017

Resumen Objetivos Determinar el comportamiento del PCA3 como un marcador de segunda linea en un programa de cribado oportunista de cancer de prostata (CaP) y su comparacion con la calculadora de riesgo 3 del cribado aleatorizado europeo en cancer de prostata (ERSPC RC-3). Material y metodos Un total de 5.199 hombres de 40-75 anos se hicieron la prueba del antigeno prostatico especifico (PSA) y un tacto rectal (TR). Aquellos con TR normal y PSA ≥ 3 ng/ml se realizaron un PCA3. Todos los hombres con PCA3 ≥ 35 se hicieron biopsia inicial (BxI) —12 cilindros—. Aquellos con PCA3 Resultados PCA3 se testo en 838 hombres (16,1%). En los grupos PCA3(+) y PCA3(–), las tasas de deteccion global de CaP…

Gynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industry030220 oncology & carcinogenesisUrology030232 urology & nephrologymedicinebusinessActas Urológicas Españolas
researchProduct

Expression of p53 Protein and Tumor Angiogenesis as Prognostic Factors in Nasopharyngeal Carcinoma Patients.

2002

The objective of this study was to evaluate the possible prognostic significance of p53 protein overexpression and tumor angiogenesis (TA) in nasopharyngeal carcinoma (NPC) patients, together with other clinicopathological variables. Forty-two NPC patients were evaluated in relation to survival. Nuclear p53 overexpression in neoplastic and endothelial cells was detected by immunohistochemistry (IHC) with the monoclonal antibody DO-7 and the polyclonal antibody against factor VIII-related antigen, respectively. Thereafter, we evaluated p53 cases in order to determine their nuclear immunoreactivity from negative (-) to positive (+, ++, +++). In addition, microvessels were counted in the most …

MalePathologymedicine.medical_specialtymedicine.drug_classBiologyMonoclonal antibodyPathology and Forensic MedicineNeovascularizationImmunoenzyme TechniquesAntigenmedicineBiomarkers TumorHumansCàncerMicrovesselSurvival analysisProportional Hazards ModelsRetrospective StudiesFactor VIIINeovascularization PathologicMicrocirculationCarcinomaNas MalaltiesCancerNasopharyngeal NeoplasmsCell BiologyMiddle Agedmedicine.diseasePrognosisPatologiaSurvival RateNasopharyngeal carcinomaCancer researchCarcinoma Squamous CellImmunohistochemistryFemalemedicine.symptomTumor Suppressor Protein p53
researchProduct

Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets

2021

In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high‐risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post‐transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker‐directed fashion.

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentRetinoic acidchemistry.chemical_compoundNeuroblastoma0302 clinical medicineTumor Microenvironment11q deletion anti-GD2 immunotherapy combination immunotherapy immune cell infiltration miRNAs neuroblastomaMedicineeducation.field_of_studyimmune cell infiltration11q deletionImmunosuppressionGeneral Medicinelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPatologiaNeoplasm ProteinsmicroRNAsSurvival Rateanti‐GD2 therapyOncology030220 oncology & carcinogenesiscombination immunotherapymiRNAsMolecular Medicineimmune checkpoint inhibitionFemaleImmunotherapyChromosome Deletionanti‐GD2 immunotherapyPopulationlcsh:RC254-282Disease-Free Survival03 medical and health sciencesImmune systemNeuroblastomaGeneticsImmune ToleranceHumanseducationRetrospective Studiesbusiness.industryChromosomes Human Pair 11Immunotherapymedicine.diseaseImmune checkpointBlockade030104 developmental biologychemistryCancer researchCommentarybusiness
researchProduct

PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme

2017

Objectives: PCA3 performance as a single second line biomarker is compared to the European Randomised Study of Screening for Prostate Cancer risk calculator model 3 (ERSPC RC-3) in an opportunistic screening in prostate cancer (PCa). Material and methods: 5,199 men, aged 40-75y, underwent prostate-specific antigen (PSA) screening and digital rectal examination (DRE). Men with a normal DRE and PSA >= 3 ng/ml had a PCA3 test done. All men with PCA3 >= 35 underwent an initial biopsy (IBx) 12 cores. Men with PCA3 = 3 ng/ml and DRE is normal, IBx could be avoided in 12.5% less than if ERSPC RC-3 is used and would reduce the false negative cases by 36.2%. At a FU of 21.7 months, this dual protoco…

AdultMalePCA3medicine.medical_specialty030232 urology & nephrologyUrologyurologic and male genital diseaseslaw.inventionOpportunistic screening03 medical and health sciencesProstate cancerPSA0302 clinical medicineSecond lineRandomized controlled trialAntigens NeoplasmlawBiopsyBiomarkers TumormedicineHumansProspective StudiesEarly Detection of CancerAgedGynecologyProstate cancermedicine.diagnostic_testbusiness.industryProstatic NeoplasmsGeneral MedicineRectal examinationMiddle Agedmedicine.diseaseProstate cancer screening030220 oncology & carcinogenesisBiomarker (medicine)PCA3business
researchProduct

Recombinacion entre los Begomovirus TYLCV y TYLCSV en Italia.

2012

TYLCD recombinacionSettore AGR/12 - Patologia Vegetale
researchProduct

Genetic variation and evolutionary analysis of Cucumber mosaic virus in medicinal, aromatic and ornamental plants from Northern Italy

2011

The genetic variation and evolution of Cucumber mosaic virus (CMV) (1) infecting aromatic, medicinal and ornamental plants in Northern Italy were studied by sequence analysis of the movement protein gene and comparison with equivalent sequences of isolates from other countries. Comparison of nonsynonymous and synonymous substitutions at each codon suggested that 30% of amino acid sites were under negative selection and only one was under positive selection. Phylogenetic inference, nucleotide diversity estimation, neutrality tests and genetic differentiation analysis revealed a high nucleotide diversity of CMV in Northern Italy with respect to areas of other countries [1,2] and suggested tha…

CMV Genetic variationPIANTE OFFICINALICMVSettore AGR/12 - Patologia VegetaleCARATTERIZIONE MOLECOLARE
researchProduct

Bayesian correlated models for assessing the prevalence of viruses in organic and non-organic agroecosystems

2017

Cultivation of horticultural species under organic management has increased in importance in recent years. However, the sustainability of this new production method needs to be supported by scientific research, especially in the field of virology. We studied the prevalence of three important virus diseases in agroecosystems with regard to its management system: organic versus non-organic, with and without greenhouse. Prevalence was assessed by means of a Bayesian correlated binary model which connects the risk of infection of each virus within the same plot and was defined in terms of a logit generalized linear mixed model (GLMM). Model robustness was checked through a sensitivity analysis …

Hellinger distancesensitivity analysisHellinger distance model robustness risk infection sensitivity analysis virus epidemiology:Matemàtiques i estadística::Estadística matemàtica [Àrees temàtiques de la UPC]:62 Statistics::62F Parametric inference [Classificació AMS]:62 Statistics::62J Linear inference regression [Classificació AMS]model robustnessvirus epidemiology:62 Statistics::62P Applications [Classificació AMS]62-07 62F15 62J12 62P10 62P12risk infectionSORT- Statistics and Operations Research Transactions
researchProduct